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Richmond Smith as a Clinical Investigator
His work on adult periosteal bone expansion and nutritional and endocrine aspects
of osteoporosis in light of current concepts
A. M. Parfitt, MB, B Chir*

This paper discusses Richmond Smith's contributions to the
field of metabolic bone disease from 1949 to 1969 in light
of current concepts. He was the first to demonstrate continuing periosteal bone expansion in adults, a phenomenon
of great biologic interest which is best explained if adult
bone remodelling is qualitatively similar on all surfaces. He
was the first to show that persons with less bone than
normal have an increased risk of subsequent fracture, and
so are more likely to benefit from preventive treatment. He
found that blood vitamin D levels were lower in osteoporotic subjects than in controls, but he concluded that this was

more likely the result than the cause of the disease. If more
people had remembered this conclusion, less harm would
have been done by the Ill-advised administration of vitamin
D and its metabolites to patients with osteoporosis. Smith
was the first to provide evidence for Albright's concept that
osteoporosis followed a shift in endocrine balance after
menopause. This topic is still being vigorously investigated,
but it seems that symptomatic osteoporosis occurs not so
much in women with the more severe endocrine changes,
but rather in those who had less bone at skeletal maturity.

R

ichmond Smith's scientific career lasted just over 20
years, beginning with his fellowship training at the Russell
Sage Institute with Ephraim Schorr, and ending with his
move from Chief of Endocrinology to Chairman of Medicine at Henry Ford Hospital.! His early work (1-3) was
mainly concerned with theclinical use and effects of ACTH
and cortisone — he was one of the pioneers in this field.
Later, his research efforts broadened within the field of
clinical endocrinology (4-6). Only during the second decade did he concentrate on osteoporosis (Table 1), but his
fascination with bone was probably kindled by early exposure to biomechanics at the Massachusetts Institute of
Technology, an interest he retained throughout his career
(7). Publications related to osteoporosis accounted for only
20% of his total output but about 50% of those for which
Smith was the senior author. His papers from this period
were cited by other scientists more than 180 times in the
decade 1970-1979. At about the same time. Boy Frame was
making important contributions to clinical parathyroid endocrinology and vitamin D resistant osteomalacia, and

Harold Frost was exploiting tetracycline labelling in vivo as
an investigative tool and developing his seminal concepts
of bone remodelling. These three individuals, in very different ways, established Henry Ford Hospital as a major
center for the study of metabolic bone disease.
TABLE I
P u b l i c a t i o n s of R i c h m o n d W. S m i t h Jr.
O v e r a 20-Year P e r i o d
E n d o c r i n o l o g y Osteomalacia

Period

Total

and
Metabolism

and Calcium
Metabolism

Osteoporosis
and Bone

1949-1954
1955-1959
1960-1964

17
7
18

17
4
11

0
3
4

0
0
3

1965-1969

13

3

2

8

Totals
Senior author
Percent

55
19

35
10
29

9
0

11
S

0

82

35

Includescontributionsto books but excludes abstracts; classified according
to subject by successive five-year periods. Note a progressive shift toward
calcium metabolism and then to osteoporosis.

tSee the short biographical profile by Dr. Raymond C. Mellinger on
pp. 93-94.

Smith concentrated on the development of osteoporosis in
asymptomatic persons, with an eye to prevention as the
best form of treatment. He was concerned mainly with
spinal osteoporosis, which traditionally falls within the
province of the endocrinologist; but since age-related bone
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loss also affects cortical bone in the extremities, osteoporosis is a major factor in the pathogenesis of femoral
neck and other fractures. His approach combined three
main elements. First, he made himself an expert in simple
methods of assessing bone status from radiographs. Second, he applied these methods to a large number of women
who were either healthy or suffering from a nondisabling
disease without any known effects on bone. Third, he
compared the bone data with the results of various nutritional and hormonal investigations in different demographic subgroups. Much current research follows similar
lines but with more complex methods for bone and endocrine measurement.
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Smith's first paper on osteoporosis (8) reported that about
30% of women over 50 years of age undergoing routine
physical examinations had radiographically detectable vertebral bone loss and about 5% had compression fractures,
both proportions increasing with age. This was the first
such study in healthy subjects; previous figures of 50% for
bone loss and 30% for compression fractures had been
obtained from residents of homes for the aged and similar
institutions. The study was based on a semi-quantitative
visual scale that combined both apparent density and
changes in vertebral shape. Subsequently, density alone
without regard to changes in shape was assessed in comparison with the soft tissues and was referred to as relative
vertebral density or RVD. Also, the numbering ofthe scale
was reversed, with Grade 3 being the best rather than the
worst (9). Although subject to many potential errors (10),
the RVD was found to be a useful predictor of subsequent
fracture experience (11), and the correlation between RVD
readings made one year apart by the same observer was
0.78 (9).
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Diagram of x-ray image of segment of a long bone. Shaded area is cortex
between (P, P^) and endosteum (E,E
Cortical thickness (CT) is difference
between external diameter (D or P, P^) and internal diameter (d or EjE^). To
avoid measuring d directly, it can be calculated from (P, E^-l- E, P^) - D, CT is
given by 2D - (P.Ej-l- E,Pj).

iology which are still not completely resolved. When the.,
data were classified on the basis of age, there was a
significant difference in periosteal diameter of 1.7 mm and
in endosteal diameter of 3.1 mm between the 45-49 year
age group and the 70-74 year age group. If interpreted as
age-related changes, cortical thickness fell from 18.7 to
17.3 mm over 25 years, but the bones grew larger with an
increase in calculated cross-sectional area from 644 to 671
m m ^ It appeared that older persons had more bone at the
femoral midshaft than younger persons, even though the
cortices were thinner! Smith interpreted this change in
biomechanical terms, to indicate stimulation of periosteal
bone formation by flexural stresses, and increased rigidity
of the femoral shaft with increasing age and consequent
greater stress on the femoral neck.

The other method used for determining bone status was
direct measurement of various dimensions on radiographs.
This was applied to the right second metacarpal, the left
femur, and the mid-lumbar vertebrae. In the metacarpal
and femur, external diameter and cortical thickness were
measured at the point of maximum cortical thickness rather
than at mid-shaft, as other investigators had done. One
problem with such measurements, especially in the metacarpal, is that the inner diameter is small and the endosteal
borders irregular. Smith partly circumvented this problem
by measuring each cortex as the difference between two
larger distances (Fig. 1). He made all the measurements
himself, and when he repeated them nine months apart he
achieved correlation coefficients of 0.90 to 0.95 (12). In the
vertebrae, he measured the AP diameter at the lower
endplate and the posterior vertical height

These interpretations have been challenged on several
grounds. Measurements on x-rays overestimate bone size,
to a variable extent, and femoral diameter measured d i rectly on 265 bones showed only half as much age-related
increase as Smith and Walker found on x-rays (14). Thickening of soft tissues with age would increase the apparent
width of the bone because of the greater distance between
the bone and the x-ray plate, but the thickness of both fat
and muscle tends to be less at age 75 than at 50. The
difference between direct and x-ray based measurement is
probably related to altered posture in elderly persons, with
small differences in rotation or mild flexion deformities of

Periosteal bone expansion with age in the adult
Analysisof the femoral measurements in 2030 subjects (13)
raised several questions of great interest for skeletal phys-
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in the adult human rib by fortuitous tetracycline labelling
(25), although data are insufficient to definitely establish
continued net growth in this bone (26).

the hip and knee joint. Direct measurements on discrete
cross-sections of the femur showed a significant decling
with age in both cross-sectional area and in calculated
structural strength in women, and either a small decline or
no change in men (15,16). Consequently, increased rigidity
of the femoral shaft is probably not a factor in causing
femoral neck fractures (16). Significant femoral expansion
has also been judged unlikely because periosteal new bone
formation is rarely seen in the femur when examined by
microradiography (17). However, this is an insensitive
method of detecting slow bone formation, and tetracycline
fluorescence has not been systematically looked for at this
site.

Periosteal new bone formation and net bone gain in the
adult, although small, must be accounted for in any comprehensive concept of bone turnover. In the adult skeleton,
within the cortex, and on endosteal and trabecular surfaces, bone formation occurs only at sites where bone
resorption has recently been completed at the same location only for about three months. By contrast, in the
growing skeleton, bone formation can occur without relation to previous bone resorption and may continue without
interruption for much longer periods of time. To mark these
important differences, adult bone turnover (which does not
appreciably alter the size or shape ofthe bones) is referred
to as remodelling, and growth-related turnover (which
substantially alters both size and shape) is referred to as
modelling (27). As in the growing skeleton, periosteal bone
apposition in the adult leads to the addition of new circumferential lamellae. This could represent persistence at a
slower rate of the same kind of modelling activity that
occurs during growth (28), with continued bone formation
without prior bone resorption. Alternatively, ason the other
bone surfaces in the adult, periosteal bone formation might
represent remodelling, with spatial and temporal coupling
to prior bone resorption (28).

A more compelling reason for doubting the occurrence of
femoral expansion with age is that in any cross-sectional
study the subjects differ not only in age but in year of birth
(18) . Consequently, the relationship of femoral diameter to
age could be explained by a generational trend for diameter to decline with later birth. For example, in the Smith and
Walker study, measurements could have been made in
1962 on a 72-year-old person born in 1890 and a 52-yearold person born in 1910. If, for some reason, there was a
decline over that 20-year period in the amount of periosteal bone accumulated during growth, with a corresponding decline in mean periosteal diameter, the older
person would have a wider femur than the younger, even
though both femurs had remained the same size after
growth stopped. When femoral measurements on a collection of 1476 skeletons were examined by partial regression
analysis for a relationship to year of birth as well as to age,
the apparent increase in femoral width with age was entirely explained by an inverse relationship to year of birth
(19) . The generational trend could be a consequence of the
well-established increase in stature or of a decline in the
level of muscular activity.

The extreme slowness of adult periosteal apposition suggests a fundamental difference from the growing skeleton.
Net apposition in the metacarpal during the first 20 years of
life averages about 150 p,m/year on both radial and ulnar
borders so that the adult rate of 2.5-5.0 p.m/year is only
1.5-3% of the rate during growth. Nothing is known about
periosteal bone cell activity in the metacarpal, but in the
adult rib about 16% ofthe periosteal surface is covered by
osteoid, indicating new bone formation (29). Ifthis proportion applies also to the metacarpal, and bone apposition
was brought about by successive periods of bone formation
without any bone resorption, the maximum rate of bone
apposition by individual osteoblasts would be less than
0.1 p,m/day (0.1 x 0.16 x 365 = 5.8 /ixm). This figure
contrasts with a measured appositional rate on endosteal
and intracortical surfaces in the range of 0.5 to 1.0 p,m/day
(30,31) and with the evidence that the appositional rate
tends to be remarkably constant from one skeletal site to
another (32,33). Furthermore, about 27% ofthe periosteal
surface in the adult rib is scalloped by Howship's lacunae,
indicating current or previous resorption (29).

Continuing periosteal expansion after growth stops, although of uncertain occurrence in the femur, has been
convincingly demonstrated in the metacarpal by two independent studies. Measurements made on serial x-ray^
taken many years apart in the same subjects showed that
the metacarpal periosteal diameter at the midpoint increased by about5-10 p,m/year for a net addition of 2.5-5.0
/i,m/year on both radial and ulnar borders (20,21). Both
cross-sectional (22) and longitudinal (20,21) studies show
that metacarpal expansion is faster in women than in men.
In the radius, continued periosteal apposition together with
slowing down of endosteal loss may actually increase the
amount of cortical bone during the ninth and tenth decades
(Johnston, personal communication). Similar longitudinal
measurements on skull x-rays showed significant expansion with age in one study (23) but not in another (24).
Periosteal new bone formation has also been demonstrated

Available data on the rib thus strongly suggest that adult
periosteal bone cell activity represents remodelling rather
than modelling. On this basis, we can formulate a unified
concept of bone turnover in the adult skeleton and ofthe
changes which occur with age. These changes include not
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only very slow net periosteal expansion but more rapid
endosteal expansion; inthe metacarpal in po.stmenopausal
women, net bone loss at the endosteal surface is about
50 pim/year, or ten times faster than the rate of periosteal
gain (Fig. 2). The difference between the surfaces is less for
bone volume because the same change in thickness produces a greater change in volume at the periosteal than at
the endosteal surface.

8mm
2mm

3mm

3mm

Age 40

The anatomic basis ofthese changes, both periosteal and
endosteal, is remodelling imbalance, the difference between the amount of bone resorbed and the amount of
bone formed by each cycle of bone remodelling activity
(34). Each cycle, or bone remodelling unit, begins with the
excavation by osteoclasts of a cavity 50-80 p.m deep,
within which osteoblasts build a new bone structural unit
(BSU). On the endosteal surface a negative remodelling
imbalance occurs, as the average new BSU is about 30%
smaller than the cavity in which it is built, the deficit
presumably diminishing with age. By contrast, on the
periosteal surface, a positive remodelling imbalance occurs, as each new BSU is about 5% larger than its cavity
(Fig. 3). For the same degree of remodelling imbalance, the
rate of gain or loss depends on the rate at which new
remodelling units are initiated, which in turn depends on
the rateof precursor cell differentiation into osteoclasts, the
ultimate determinant of the rate of bone turnover.

_/

/

/

/

\
\
\

Age 70
5.0mm
8.3mm

mm

1.65n^m

Fig. 2
Diagram to show changes in metacarpal cortical dimensions w i t h age in a
representative white w o m a n . In 30 years the external (periosteal) diameter (D in Fig. 1) increases by 0.3 mm, the internal (endosteal) diameter (d in
Fig. 1) increases by 3.0 m m , and cortical thickness (D-d) decreases by 2.7
m m . Assuming the bone is cylindrical, cortical cross-sectional area as a
fraction of total cross-sectional area (CA/TA) decreases from 0.937 to
0.637, or just over 10% of the initial value per decade.

This analysis is pertinent to understanding some of the
effects of parathyroid hormone (PTH) on bone. In both
primary hyperparathyroidism and in the secondary hyperparathyroidism of early chronic renal failure (35), periosteal and endosteal metacarpal diameters are greater, and
metacarpal cortical thickness smaller than in age- and sexmatched controls (Table II, Fig. 4). If periosteal expansion
were due to bone formation alone, these data would imply
that parathyroid hormone directly or indirectly stimulated
periosteal osteoblasts. However, if periosteal expansion
results from positive remodelling imbalance between resorption and formation, an increase in precursor cell proliferation and consequently in the number of remodelling
units initiated in unit time will inevitably accelerate the rate
of periosteal expansion. Thus, the increased rate of both
periosteal gain and endosteal loss could be explained by
the same action of PTH to increase bone turnover, so that
no additional effects of PTH on differentiated cell function
need be postulated (36). Similarly, the increased bone
turnover that occurs with estrogen deficiency (37) will
account for the faster metacarpal periosteal gain in women
than in men (22) and forthe finding of Saville, etal (38) that
femoral diameter correlated with years after menopause
but not with age, an observation difficult to explain on a
generational basis.

Periosteal

Endosteal

Old bone

I New bone

Fig. 3
Diagram showing construction of new bone structural unit on periosteal
(P) and endosteal (E) surface of a long bone: 1) quiescent surfaces;
2) Howship's lacunae (HL) w i t h location of onginal surfaces as dotted
lines; 3) completed bone structural units (BSU) w i t h cement lines (CL)
indicated. The BSU Is larger than the cavity in which it is formed on the
periosteal surface (positive remodelling imbalance) and smaller on the
endosteal surface (negative remodelling imbalance). Since the average
BSU changes little in size, the rate of change of bone mass in each surface
depends on the number of new BSU made in unit time. This depends on
the rate of precursor cell differentiation into osteoclasts and is unrelated
to the rate at which differentiated cells do their work.
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T A B L E II

Outer Diameter

M e t a c a r p a l C o r t i c a l D i m e n s i o n s in P r i m a r y H y p e r p a r a t h y r o i d i s m
a n d C h r o n i c R e n a l Failure

Variable

L(mm)
A
E
Difference
P
D(mm)
A
E
Difference
P
d(mm)
A
E
Difference
P

HPT(41)
mm

Primary
Hyperparathyroidism
(n=41)

Chronic Renal Failure
(n=86)

65.28 ± 4.68
65.71 ± 2.57
+0.57 ± 0.53
ns

65.61 ± 5.01
65.69 ± 2.69
- 0 . 0 8 ± 0.43
ns

9.31 ± 1.15
8.55 ± 0.62
-1-0.76 ± 0.12
<0.001

8.93 ± 0.85
8.53 ± 0.61
-1-0.40 ± 0.07
<0.001

4.96 ± 1.19
3.29 ± 0.48
-1-1.67 ± 0.18
<0.001

4.45 ± 0.96
3.29 ± 0.55
+ 1.16 ± 0.08
<0.001

O

E

CRF(86)

O

E

Cortical Thickness
HPT(41)

O

E

CRF(86)

O

E

lO.On

8.0

CT(mm)
A
E
Difference
P

4.35 ± 0.76
5.26 ± 0.45
- 0 . 9 1 ± 0.09
<0.001

CA/TA
A
E
Difference
P

71.29 ± 9.06
84.00 ± 3.39
- 1 2 . 7 1 ± 1.23
<0.001

6.0-

4.0-

2.0-

Fig. 4
Increased metacarpal periosteal diameter and decreased cortical thickness in 41 patients w i t h primary hyperparathyroidism (HPT) and 86
patients w i t h chronic renal failure (CRF) and presumed secondary hyperparathyroidism, studied in Brisbane, Australia. 0 = o b s e r v e d mean value
(+SE). E=expected mean value ( + SE) in subjects of same age, sex, and
race; none of the patients were black. The mean metacarpal length (Table
II) was not increased, so that the increase in w i d t h was not due to a
difference in body size. The increase was significant whether compared
w i t h normal subjects in the United States or in Belgium, or w i t h
hypoparathyroid patients in Australia (35).

4.47 ± 0.81
5.24 ± 0.45
- 0 . 7 7 ± 0.08
<0.001
74.55 ± 8.69
83.82 ± 3.75
- 9 . 2 7 ± 0.78
<0.001

L = length of second left metacarpal
D = outer diameter at midpoint
d = inner diameter at m i d p o i n t
CT = cortical thickness given by D-d

tive study, he showed that fractures of all kinds were twice
as common in the subsequent three years in women with
low RVD values as in women with normal values, but that
for the same vertebral density the incidence was unrelated
to age (11). Based on these data, he made the first appraisal
o f t h e global social and e c o n o m i c i m p o r t a n c e of osteoporosis, estimating that in the U.S. alone its prevention
would avert at least 350,000 fractures per year.

CA/TA = cortical cross-sectional area as a percentage of total crosssectional area given by (D^-d^): 100/D^
A = actual results compared with age and sex-expected values (E)
means ± SD, differences ± SEM

Epidemiologic and nutritional studies on osteoporosis

Richmond Smith's studies on nutrition and osteoporosis are
still germane to current discussions of pathogenesis. With
Boy Frame, he found no difference in metacarpal or
femoral cortical thickness or relative vertebral density
among white women with low, medium, or high calcium
intakes in the range of 300-1500 mg/day, the different
groups being matched for age, height, and weight (9).
Similarly, calcium intake did not differ between women
with low or high RVD values. Although these data have
never been refuted, they are in apparent conflict with the
recent demonstration that postmenopausal women need a
daily calcium intake of at least 1500 mg to remain in zero
external calcium balance (39,40). On the average, women
with low intakes were in negative calcium balance and so
losing bone, while those with high intakes were in positive

The controversy which still surrounds Richmond Smith's
observations on femoral expansion and their interpretation
contrasts with the extent to which many of his other
observations have been incorporated into the general body
of k n o w l e d g e about age-related bone loss and osteoporosis. He confirmed earlier suspicions that blacks were
less prone to osteoporosis than whites, with a higher
relative vertebral density at all ages, a lower prevalence of
vertebral compression fractures, and a slower fall in metacarpal cortical thickness with age (12). He was the first to
demonstrate in a statistically adequate manner the lower
prevalence of vertebral osteophytosis and higher prevalence of aortic calcification in osteoporotic subjects than in
controls of the same age, sex, and race (12). In a prospec-
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balance and so either gaining bone or depositing calcium
in soft tissue. Although some of the deviations from zero
balance might have reflected adaptation to unrecognized
changes in intake, significant differences in apparent calcium requirement were found when the same women were
studied before menopause and again five years later.

TABLE III
Effect of Geographic Location, Season, and Bone Status
on Serum Bio-Assayable Antirachitic Activity*

Smith and Frame's cross-sectional data must also be reconciled with longitudinal studies showing that calcium supplements (41,42) can provide significant protection against
postmenopausal cortical bone loss. Equally paradoxical
are the results of e p i d e m i o l o g i c observations from
Yugoslavia (43). Persons living in areas of low and high
calcium intake differed modestly in bone mass at skeletal
maturity, but the difference diminished with increasing age,
suggesting that bone loss in those with low intake was
slower than in those with high intake! Some of these
paradoxes might be resolved if more attention were paid to
effects of different sources and chemical forms of calcium
and to other dietary constituents such as phosphorus and
protein, but the most likely explanation has to do with the
relative importance in the pathogenesis of osteoporosis of
bone gain during growth and bone loss in later life. Since
bone loss conforms approximately to an e x p o n e n t i a l
model (44), its rate is governed partly by the amount of
bone present at skeletal maturity. Bone mass at maturity is
probably the main determinant of whether clinically significant osteoporosis does or does not occur, as variations
in the rate of bone loss contribute less than has been
generally assumed.

Summer

Puerto Rico
Winter

Normal
(RVD O o r i )

High

High

High

Low

Osteoporosis
(RVD 2 or 3)

High

High

Low

Low

Michigan
Summer
Winter

*Summary of data of Smith, Rizek, and Frame (45).

virtually nothing was known about vitamin D metabolism.
We now know that vitamin D, whether made in the skin in
response to sunlight (cholecalciferol or D3), or ingested in
the diet (mainly ergocalciferol or D2), is converted in the
liver to a 2 5 - h y d r o x y metabolite (either 2 5 - h y d r o x ycholecalciferol (25HCC) or 25-hydroxy-ergocalciferol
(25HEC)), which is the main transport and storage form.
25-hydroxy-D is then converted in the kidney to a dihydroxy derivative (either 1,25 dihydroxycholecalciferol
(1,25DHCC) or 1,25-dihydroxy-ergocalciferol (1,25DHEC),
which is the main biologically active metabolite. When
human serum is injected into a rachitic rat, any parent
vitamin or 25-hydroxy D present is converted into 1,25dihydroxy D so that the total bio-assayable antirachitic
activity represents the sum of all three forms in the test
serum. The levels of vitamin D and 25-hydroxy D are much
more variable than the level of 1,25-dihydroxy D, which is
tightly controlled by a complex homeostatic system. The
earlier data for SARA correspond to current measurements
of 25-hydroxy D (25 HEC + 25 HCC), which is the simplest
index of vitamin D status and shows much the same sort of
geographic and seasonal variation as SARA.

Vitamin D metabolites and osteoporosis
Smith and his colleagues were the first to systematically
study vitamin D in relation to osteoporosis (45), a subject of
great current interest because of the great advances in the
last decade in understanding vitamin D metabolism (46).
Using a well-standardized bio-assay in the rachitic rat, they
studied serum antirachitic activity (SARA) in women from
subtropical Puerto Rico and from temperate Michigan
(Table III). In Puerto Rico the mean SARA was 4.40 ±0.4
l U / m l ; it showed no seasonal fluctuation and increased
slightly with age. In Michigan the mean value was significantly lower at 2.6 ±0.2 lU/ml and fell significantly with
age. Healthy women in Michigan showed a significant
seasonal variation, with values similar to those of Puerto
Rican women in the summer. However, in Michigan subjects with low RVD values, this summer increase did not
occur; therefore they had lower SARA levels than Puerto
Rican subjects throughout the year. However, in Puerto
Rico there was no difference in SARA between those with
normal and those w i t h low RVD values.

Nutritional or climatic vitamin D deficiency may have a
role in the pathogenesis of osteoporosis in the very old,
since plasma 25-hydroxy D levels are significantly lower in
patients with hip fractures than in controls matched for age,
sex, and race (47,48). Predisposition to hip fractures as a
function of vitamin D deficiency is most likely due to
impaired calcium absorption, which leads to mild secondary hyperparathyroidism and accelerated loss of cortical
bone; it is unrelated to the presence or absence of defective
bone mineralization or osteomalacia. It is unlikely that
nutritional or climatic vitamin D deficiency was concerned
in the pathogenesis of low vertebral bone density in ambulant persons who were about 15-20 years younger than
patients with hip fractures, many of whom live in nursing
homes or other institutions for the aged. Smith and his
colleagues offered several more likely explanations for low
SARA values in osteoporotic Michigan women—either
avoidance of sunlight by fair-skinned women who are
more prone to osteoporosis, or restriction of activity because of pain and disability (45).

When these data were obtained, it was believed that vitamin D acted directly on target cells in gut and bone, and
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The possible role of 1,25-dihydroxy D in the pathogenesis
and treatment of osteoporosis is controversial. Reduced
intestinal calcium absorption, which is found in osteoporotic subjects as a group, is ascribed by some to low plasma
levels of 1,25DHCC (49) and by others to an intestinal
transport defect unrelated to 1,25DHCC (50). Estrogen
deficiency sensitizes bone to the effects of parathyroid
hormone, leading to a slight rise in plasma calcium and a
modest increase in bone turnover despite a decline in PTH
secretion (51). Because PTH is one o f t h e main regulators
of 1-hydroxylation of 25-hydroxy D, low PTH levels would
account for low 1,25DHCC levels; indeed, estrogen replacement therapy may be followed by a rise in PTH,
1,25DHCC, and calcium absorption (52). In man, renal
function declines with age, and in the rat there is an agerelated depression of 1,25DHCC synthesis (53). For whatever reason it occurs, intestinal malabsorption of calcium is
much more easily corrected by 1,25DHCC than by vitamin
D, which is either totally ineffective or actively harmful in
treating osteoporosis (54,55).

toward "catabolic" preponderance in the postmenopausal
state was important in the pathogenesis of osteoporosis.
Before the current status ofthis concept can be examined, a
brief account must be given o f t h e changes in ovarian and
adrenal function which occur with the normal menopause;
these are more extensive than a simple loss of estrogen
secretion (Table IV). During reproductive life, estradiol is
the principal estrogen in plasma. The concentrations of
both estradiol and estrone vary with the menstrual cycle
from a low basal level in the early follicular phase to a peak
just before ovulation (59,60). In the five years or so before
menopause, the peak estrogen level gradually declines
until it is about half the young adult value (61). When
menstruation ceases, ovarian production of estrogen has
virtually ended, and the cyclical increases in plasma concentration no longer occur, but there is a persistent basal
level which decreases slowly with advancing age. In the
postmenopausal woman, the plasma level is higher for
estrone than for estradiol. Both estrogens are derived from
androgen precursors (62,63), estrone from androstenedione and estradiol from testosterone (Fig. 5). These conversions take place mainly in fat and muscle (64,65); their
efficiency is directly related to body weight and increases
with age (59,63). About two thirds of daily androstenedione production is secreted by the adrenal and about one
third by the ovary. By contrast, about two thirds of daily
testosterone production is secreted by the ovary (66) antd
about one third is derived from conversion of androstenedione in the liver. Plasma androgen levels are significantly
reduced after the menopause (67,68), but only about
1-3%of daily androgen production is converted to estrogen.
If the premenopausal estrogen secretion rate is averaged
throughout the menstrual cycle, the fall after the men-

Endocrine aspects of osteoporosis
Richmond Smith was among the first to examine systematically Fuller Albright's proposal 25 years earlier (56)
that osteoporosis was largely the result of postmenopausal
gonadal hormone deficiency and consequent relative excess of "catabolic" glucocorticoid. His extensive endocrine studies, never published in full, were presented
somewhat out of context at a symposium on nutrition and
bone loss (57).
Neither relative vertebral density nor metacarpal cortical
thickness were significantly related to age of onset of
menstruation, number of pregnancies or births, duration of
lactation, or age at or type of menopause; thus, reproductive endocrine function during earlier life had no effect on
current bone status. Vaginal cytology as an index of residual estrogen production was slightly more atrophic in
osteoporotic subjects, but there was a large overlap. Pituitary gonadotropin excretion was significantly higher and
testosterone glucuronide excretion and retrospectively determined axillary hair growth significantly lower in subjects
with low RVD values. In agreement with earlier studies
(58), basal urinary excretion rates of various other androgenic steroids and glucocorticoids and their metabolites
did not differ significantly between different grades of RVD.
However, in response to ACTH, osteoporotic subjects had
a relatively greater increase in Cortisol than in androgen
secretion as judged by urinary metabolite excretion; in
response to insulin-induced hypoglycemia, they had a
subnormal rise in plasma growth hormone. Collectively
these data provided the first objective support, albeit modest, for Albright's concept that a shift from "anabolic"

T A B L E IV
Effect of M e n o p a u s e on B a s a l P l a s m a L e v e l of
E s t r o g e n s and A n d r o g e n s (67)

Before
Menopause

After
Menopause

Number

15

20

Age

18-25

51-65

Estrogen
Estrone
Estradiol

58
40

49
20

Androgen
DHEA
Androstenedione
Testosterone
DHTestosterone

5420
1660
440
300

990
300

- 1 5 (NS)
-50
1970

too

Percent
Change

-64
-40
-32
-67

Premenopausal values obtained during early follicular phase lasting from
the M t h to the 10th day before the plasma LH peak (in pg/ml); during the
rest of the cycle, the mean total estrogen level would be about four times
higher and the peak level about ten times higher.
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TABLE V
P r e g n e n o l o n e 1 7 0 H Pregnenolone — ^ DHEA

i

i

Effect of Menopause on Time-Averaged Plasma Levels
and Production Rates of Estrogen

^ Androstenediol

i

i

i

Cortisol

Estrone 4

After
Menopause

Percent
Change

100
200
300

40
20
60

-60
-90
-80

Mean production rate (fig/day)
Estrone
200
Estradiol
400
Total estrogen
600

40
20
60

-80
-95
90

Before
Menopause

Progesterone-H70H Progesterone-> Androstenedione-•Testosterone

i

Mean plasma level (pg/ml)
Estrone
Estradiol
Total estrogen

•Estradiol

DHEA = Dehydroepiandrosterone

Fig. 5
Interrelationships between steroid hormones w h i c h may tie important in
the pathogenesis of osteoporosis. In the normal postmenopausal woman,
androstenedione is derived predominantly from adrenal secretion (twothirds) and ovarian secretion (one-third); testosterone is derived predominantly from ovarian secretion (two-thirds) and from conversion (onethird) of androstenedione in the liver; estrone and estradiol are derived
almost exclusively from conversion of their androgen precursors in fat and
muscle.

Values are approximations compiled from several sources. Premenopausal
values are derived from published data for different stages o f t h e menstrual
cycle.

This relationship is so unequivocal that is seems surprising
that it could ever have been doubted, but in fact the doubts
were justified; their reasons concern the important distinction between the process of bone loss and the clinical state
of osteoporosis (72). The crucial question to be answered is
how can a physiologic process which occurs in every
woman be the cause of a disease which affects only a
minority? (51,68) In patients who have well-established
osteoporosis with one or more nontraumatic vertebral
compression fractures, the mean age at cessation of menstruation isthe same as in control subjects, and the correlation between this age and the age of onset of symptoms,
although significant, is low (73); in individual patients the
time interval can vary from three to 30 years. There are also
other objections to regarding menopause as the sole determinant of either spinal osteoporosis or of osteoporotic
femoral neck fractures (68).

opause is about 90% (Table V), but when basal plasma
levels only are compared, the relative falls in androgen and
estrogen are quite similar. As indicated in Table IV, all
hormones except estrone are significantly lower (P<0.01)
in the postmenopausal subject than during the early follicular phase in young women (67). Other studies have
shown similar changes in estrogen and androgen levels, as
well as a significant fall in 17-OH pregnenolone, progesterone and 1 7 - O H progestrone, but no significant
changes in Cortisol or corticosterone (68).
Over the years, many investigators have quibbled with
the term postmenopausal osteoporosis that Albright (56)
coined because it implied an unproven etiological relationship, but recent studies have thoroughly vindicated his
deductions. Sequential measurements by various techniques have demonstrated a clear-cut relationship between
cessation of cyclical ovarian function and accelerated loss
of bone (41,42,69,70). The loss is fastest immediately after
menopause, spontaneous or induced, and in the first year it
may be as high as 3%of initial mass in the predominantly
cortical bone of the radius (41) or metacarpal (69), and
10%of initial mass in the trabecular bone ofthe spine (70).
The rate of loss is greater for mineral content (41,69) than
for cortical thickness (42), reflecting the increase in intracortical porosity which follows increased turnover (36).
The rate of loss declines progressively in subsequent years.
In adequately controlled prospective studies, the early
phase of rapid loss can be completely prevented by estrogen replacement, whereas a placebo is without effect
(41,42,69). If estrogen treatment is stopped after several
years, accelerated bone loss follows, similar in timing and
magnitude to the usual postmenopausal bone loss, so that
the benefits of treatment may be completely nullified (71).

The paradox that accelerated bone loss is clearly related to
the menopause, whereas symptomatic osteoporosis is not,
probably has several explanations. The amount of bone is
not the only determinant of fracture risk; bone cell function
and bone quality are also important (55,74). Estrogen
deficiency initiates and sustains accelerated bone loss, but
the rate of loss is influenced by other factors as well.
Indeed, since there are no estrogen receptors in bone (75),
the effects of estrogen deficiency and replacement must be
indirect, although their mediators are unknown. Plasma
calcitonin levels vary with estrogen status in several situations (76,77). Thyroidectomy is not known to be followed
by increased bone turnover or accelerated bone loss, but
the effect of chronic calcitonin deficiency on bone in
euthryoid patients with normal parathyroid function has
not been systematically examined. Intestinal malabsorption
of calcium may be an additional independent risk factor for
bone loss (78), but it may also be an adaptation to obligatory loss of calcium from bone. As mentioned earlier, some

102

Richmond Smith as a Clinical Investigator

investigators find plasma levels of 1,25DHCC lower in
patientswith osteoporosis than in controls, butothers have
found no difference.

are concerned in the pathogenesis of osteoporosis (86), the
relationship is still by no means certain. As is true for
estrogen, there are no androgen receptors in bone, so that
their effects on bone must be indirect. Skinfold thickness
decreases after menopause, and the skin is thinner (54) and
more transparent (87) in osteoporotic than in control subjects. Skin thickness is at least partly dependent on total
collagen content, which is reduced in patients with osteoporosis, a defect which can be partly corrected by
androgen administration (88). The lower plasma androstenedione levels in osteoporotic patients than in controls
(83) represent declines of about 60% and 40%, respectively, from the normal premenopausal level, a much
greater relative difference than for estrone. The bone mineralization rate determined by radiocalcium kinetics is
correlated both with plasma androstenedione and skinfold
thickness. For all three measurements, patients w i t h
postmenopausal osteoporosis were intermediate between
normal subjects and corticosteroid-treated patients (54).
Androgen deficiency might impair osteoblast function, or
more likely, the recruitment of osteoblasts from precursor
cells (89). Despite these findings, two independent studies
showed no difference in plasma levels of androstenedione
or testosterone between fast and slow losers (44,84). Furthermore, the suggestion that fast losers have higher levels
of free androstenediol (estimated as the ratio of androstenediol to sex hormone-binding globulin) (90) was not
confirmed (84).

The severity of postmenopausal deficiency of both estrogen
and androgen varies between subjects. The extent to which
androgen precursors are converted to estrogen varies with
body weight, whether the changes are in adipose tissue or
muscle, but variation in plasma androstenedione level is
probably more important in determining estrogen status
(79). The ovarian contribution to total androstenedione
production declines at varying rates after the menopause
and is totally eliminated by oophorectomy, but variation in
the adrenal contribution is more important. The reasons for
this variation are unknown; differences in adrenal androstenedione secretion are probably not due to differences in adrenal cell mass or degree of stimulation by
ACTH and are not accompanied by differences in Cortisol
secretion. For u n k n o w n reasons the adrenal in some
women produces mainly androstenediol, which may act as
an anti-estrogen (80), rather than androstenedione.
The importance of differences in estrogen status in the
pathogenesis of osteoporosis is unresolved. Smith's observation that severity of vaginal atrophy correlated with
relative vertebral density was c o n f i r m e d (81), but the
plasma levels of total estrogen and testosterone were the
same in patients with osteoporosis and in age-matched
controls (82). When matched for years after menopause
rather than for age, osteoporotic patients had significantly
lower values for plasma androstenedione and plasma estrone than controls (83), but the mean difference was only
about 25% with a large overlap. Assuming the same premenopausal estrogen status, the difference in plasma estrone levels represents a decline in mean estrogen
production rate of about 92% in the patients with osteoporosis and about 90% in the controls. Unless a critical
threshold value must be reached, it seems unlikely that this
difference could account for the presence or absence of
vertebral compression fractures. A final piece of evidence
comes from a study of fast losers and slow losers, defined
by serial metacarpal mineral measurements after bilateral
oophorectomy (84). No significant difference in plasma
estrone or estradiol was found between the two groups
(84), reversing the conclusions of an earlier study from the
same laboratory (85). The same lack of difference was
found between fast losers and slow losers defined by
photon absorptiometry of the radius (44). It must be acknowledged, however, that hormonal dependence may be
different forthe mainly cortical bone ofthe extremities than
for the mainly trabecular bone of the spine.

Progesterone may also be important in determining differences in the rate of bone loss among postmenopausal
women. Although this hormone has received far less attention than either estrogen or androgen, its mean plasma
concentration decreased by more than 60% after menopause (68). Progestogens prevent bone loss in oophorectomized rats (91) and have effects similar to estrogen on the
urinary excretion of calcium, phosphate, and hydroxyproline in postmenopausal women (92). Metacarpal mineral loss in postmenopausal women was prevented by a
progestogen (19-nor-17- hydroxy progesterone 17-caproate) as effectively as by an estrogen (mestranol), despite a
much smaller effect on urinary hydroxyproline excretion
(93) . In one study (44), plasma progesterone was significantly lower (by 47%) in fast losers than in slow losers, but
in the other there was no difference between fast and slow
losers in plasma progesterone, pregnenolone, or in their 17O H derivatives (84).
There are many similarities between steroid-induced and
postmenopausal osteoporosis (54), and of the steroid hormones shown in Fig. 5, only Cortisol has receptors in bone
(94) . Glucocorticoids also interact with receptors in bone
for other hormones, and so may enhance their bone resorbing effect; degradation of 1,25DHCC receptors is inhibited

A l t h o u g h Smith's data and other earlier studies (58)
provided some evidence that differences in androgen status
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(95), and the cyclic adenosine monophosphate response to
PTH is enhanced (96). Plasma Cortisol does not increase
after menopause (68) and does not correlate with the rate of
bone loss (84), but urinary free Cortisol, a more accurate
indicator of the integrated Cortisol secretion rate than the
plasma level, was significantly higher in the fast losers than
in the slow losers (84,97). Despite this, the plasma Cortisol
increment in response to ACTH was less in the fast losers,
although the changes in plasma levels of several androgens
were no different between the two groups. In contrast to
Smith's data, this suggests an extra-adrenal rather than an
adrenal reason for increased Cortisol secretion in subjects
with more severe bone loss; however, in the more recent
studies, the urinary excretion rates of Cortisol and of androgen metabolites after ACTH were not measured. Cortisol may also modify the response to treatment; plasma
Cortisol level more than doubles with estrogen treatment
and the rise is greatest in patients with the poorest response
(98).

most likely explanation, as for the different estimates of the
importance of dietary calcium intake, is that differences in
the amount of bone accumulated during growth are a more
important determinant of bone mass in later life than
differences in the rate of loss, even though the rate of loss is
proportional to initial mass. This is probably so at least for
the first 15-20 years after menopause; only in the very old
does the rate of loss become the major factor that determines the risk of fractures.
At first sight, this may seem a nihilistic conclusion, since for
present patients the past cannot be changed, and for future
patients we still do not know how to increase bone accumulation during growth. But if bone mass at maturity is
the major determinant for the risk of compression fractures,
we can then adopt relatively simple methods of determining those women at greatest risk who would benefit most
from prophylactic treatment, e.g., with estrogen or calcium, possibly combined with a 1-hydroxylated derivative
of vitamin D. At present, estrogen prophylaxis is under a
cloud, due to evidence that it increases the risk of endometrial cancer (101). However, for every death from endometrial cancer, there are 10 to 15 deaths from hip fracture.
In England, it is estimated that about 30% of women will
sustain a fracture of either a vertebra, a long bone, or a
femoral neck by age 75 (54). Similar calculations cannot be
made in the United States, but fracture experience, where
determined, is similar to that in England. It is clear that
optimal calculation of the balance of risks and benefits of
prophylactic treatment for individual patients would be a
public health measure of considerable importance. As was
once asked many years ago in the British Parliament — if
preventable, why not prevented?

The only hormone Smith studied which has received little
attention is growth hormone. This has been tried unsuccessfully in treatment when given alone (99), and with
modest success in combination with calcitonin (100), but a
systematic study of its importance in the pathogenesis of
osteoporosis is still lacking. The role of estrogen deficiency
is much clearer than it was in 1967, although its mode of
action is still unknown, and the role of other steroid
hormones is still uncertain. Of the conclusions that could
be drawn from Richmond Smith's studies, none have been
refuted, and suggestive further evidence has accumulated
for several of them.
Nevertheless, none ofthe studies discussed has provided a
convincing resolution of the paradox presented earlier. The
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